There’s a certain thrill to a sweeping medical heresy. Say the right words—“scam”, “Big Pharma”, “we’ve all been misled”—and people lean in. A Midwestern Doctor’s latest entry, “Unmasking The Great Blood Pressure Scam,” plays expertly with that energy. It asks a fair question: if blood pressure is so central to modern medicine, why does so much about it feel… messy? Readings vary wildly. Cuffs are the wrong size. Targets move downwards every decade. Drugs often multiply, the side-effects pile up, and the promised benefits can feel abstract.

There’s plenty in the essay that deserves an airing. Measurement is frequently flawed. Overtreatment is a real risk, especially in the elderly. Class effects differ; some antihypertensives do more good than others for certain outcomes. Salt advice is over-simplified for the public. And white-coat hypertension is common enough to change individual decisions.

But does that add up to a “scam”? Not quite. When we step back from anecdotes and sift the strongest evidence, the core claim—that blood pressure treatment mostly doesn’t prevent heart disease and merely nudges stroke—doesn’t stand. The modern trial record is considerably less conspiratorial and more, well, boring: lower blood pressure tends to mean fewer major cardiovascular events across the board, with caveats about who, how far, and at what cost. That fuller picture is messier than a slogan, but it’s also more useful.

Below I work through the strongest points in the piece, where they land, and where they overreach.

1) The measurement muddle is real—and consequential

If you’ve ever had your blood pressure taken in a hurry, you’ve probably experienced one of the standard sins: wrong cuff size, crossed legs, a rushed single reading after you’ve just rushed in. Those details matter. Professional statements note that using an undersized cuff can materially over-estimate blood pressure. Add to that white-coat hypertension (higher readings in medical settings), and you have an obvious pathway to over-diagnosis and overtreatment. Recent reviews suggest white-coat hypertension is relatively common and not benign, but still distinct from sustained hypertension—hence the push for home or ambulatory confirmation before slapping on a label. (PMC)

Emergency departments have also cooled on the reflex to “treat the number.” For patients with very high readings but no evidence of acute organ injury, rapid blood-pressure lowering hasn’t been shown to improve outcomes and may even reduce brain perfusion. “Treat the patient, not the number” is now the line—titrate thoughtfully, arrange follow-up, and confirm the diagnosis out of the adrenaline-charged setting. (NCBI)

So yes: the author is right that sloppy measurement—and the anxiety it induces—can turn healthy people into patients. The conservative instinct here is sound: confirm hypertension with good technique and out-of-office monitoring before lifelong treatment.

2) Does lowering blood pressure prevent only strokes? No—the benefits are broader

The centrepiece claim in the essay is stark: outside of severe situations, treating blood pressure “has never been proven to reduce heart disease,” just stroke. That’s not supported by the largest, best-conducted evidence we have.

Two huge meta-analyses pooling individual participant data from dozens of randomised trials found that for every 5 mmHg fall in systolic blood pressure, the risk of a major cardiovascular event fell by roughly 10%, with consistent reductions in coronary heart disease, stroke, and heart failure, across age groups and baseline pressures. A 10 mmHg drop scaled to ~20% fewer major events and a 13% fall in all-cause mortality. Those effects weren’t confined to the very high blood-pressure end of the spectrum. This isn’t pharmaceutical PR; it’s the Lancet’s most conservative machinery grinding through hundreds of thousands of patient-years. (The Lancet)

The SPRINT trial, which compared a systolic target of <120 versus <140 mmHg in high-risk adults (without diabetes), found significantly lower rates of major cardiovascular events and all-cause mortality in the intensive group. That’s heart attacks included, not just strokes. The sting in the tail? More hypotension, syncope, electrolyte issues and acute kidney injury—the trade-offs the author emphasises, and rightly so. (New England Journal of Medicine, PubMed)

This is the proper tension: benefits are real, but so are harms. Which brings us to targets.

3) “Lower is always better” vs age- and risk-sensitive thresholds

The essay leans on an older re-analysis of Framingham data (Port et al., 2000) arguing for an age- and sex-dependent threshold effect rather than a tidy linear “the lower the better” model. The paper is interesting and did challenge dogma at the time. (PubMed)

But once again, the subsequent trial landscape changes the picture. Across IPD meta-analyses and trials like SPRINT, the average relation between achieved blood-pressure reduction and risk looks approximately continuous: a given decrement in systolic pressure tends to yield a fairly constant proportional reduction in major events, irrespective of starting level—though absolute benefit is bigger in higher-risk people. That doesn’t mean everyone should chase 110 mmHg. It does mean that the main question is who stands to gain, how much, and what they might pay in adverse effects. (The Lancet)

A conservative approach here is not to throw out the continuous risk model, but to insist on shared decision-making that respects frailty, polypharmacy, falls risk, and the patient’s tolerance for side-effects.

4) Drug classes behave differently—so don’t worship the number

One of the better points in the essay is that not all classes are equal, even when the clinic number drops the same. That’s true. For example, pooled analyses suggest β-blockers are generally inferior to other first-line classes for preventing stroke and major cardiovascular events in straightforward hypertension. Diuretics are strong for preventing heart failure; calcium-channel blockers are particularly effective for stroke. The broad lesson: the number is not the whole story; mechanism matters. (The Lancet)

This also dovetails with real-world harms the author highlights. In older patients, antihypertensives are associated with more serious fall injuries, particularly at moderate to high treatment intensity—an observational finding that aligns with what any geriatrician sees on the ward. (Cochrane Library)

So we should be choosy: pick classes that match comorbidities (e.g., ACE inhibitors in diabetics with albuminuria; diuretics where volume is the main driver), avoid piling on for marginal gains, and de-escalate when frailty bites. This is medicine, not a league table.

5) White-coat, masked, and the central–peripheral wrinkle

The author notes two subtleties that clinicians sometimes gloss over:

• White-coat hypertension is common; masked hypertension (normal in clinic, high at home) also exists. Because outcomes diverge by phenotype, guidelines increasingly recommend home or ambulatory monitoring before diagnosis and after starting therapy. That’s simply good practice—especially in young or anxious patients. (PMC)
• Central (aortic) pressure can differ from arm-cuff readings and may map more closely to risk in some settings. Different drugs shift central and peripheral pressures by different amounts; that’s one reason equal brachial readings can yield unequal outcomes. The general point supports the author’s theme: context matters. (Clinically, though, we still mostly treat off brachial numbers because that’s what the trials used.)

Neither subtlety makes hypertension treatment a charade. But both warn against lazy, single-reading medicine.

6) Salt: the awkward evidence and the easy myth

Public messaging on salt is often simplistic: “less salt is good for everyone.” The evidence is more nuanced. Randomised trials and meta-analyses consistently show that reducing sodium intake lowers blood pressure, with larger effects in people with hypertension. The DASH-Sodium feeding study and other pooled analyses found reductions of several mmHg for modest sodium cuts—small per person, large in population terms. National programmes cutting average intake have been linked to big falls in stroke and heart disease mortality. (NICE)

But two cautions deserve mention. First, some large observational work (for example, the PURE cohort) has suggested a J-shaped association between estimated sodium intake and outcomes—highest risks at very high intakes, but also signals of risk at very low intakes in some populations. (These studies are contested because measuring usual sodium precisely is hard.) Second, clinicians do under-recognise hyponatraemia risk when they slash sodium and add diuretics in older or comorbid patients.

The sensible stance? Avoid scare campaigns. Encourage less ultra-processed food (most dietary sodium lives there), consider potassium-enriched salt where appropriate, and individualise advice for people prone to low sodium or orthostatic symptoms. What we shouldn’t do is infer from the existence of nuance that salt doesn’t matter at all.

7) Causes: “essential” doesn’t mean unknowable, and secondary drivers are commoner than we think

The label essential hypertension still covers most cases; it doesn’t mean “mystical,” it means multifactorial—genes, age-related arterial stiffening, kidney and vascular biology, and environmental factors like poor sleep and inactivity. Meanwhile, secondary causes such as renal artery stenosis (activating the renin–angiotensin system) and sleep problems (which impair vascular function and raise BP even after a single bad night) are real and probably under-recognised in the rush for quick fixes. (Lippincott Journals, ATS Journals)

A cautious clinician checks for those levers early—treating sleep apnoea, for example, can nudge blood pressure down and improve overall risk without adding another tablet.

8) Zeta potential, “blood sludging,” and the temptation of a single grand theory

Here the essay wanders into territory that is more speculative than it admits. Red-blood-cell aggregation and cell-membrane properties (often discussed in terms of zeta potential) are legitimate biophysical ideas. Inflammation and various diseases can change blood rheology; microcirculatory dysfunction matters. But the step from those observations to “zeta potential explains most hypertension” (or vaccine injuries, or microstrokes) is a leap. The peer-reviewed literature correlating erythrocyte aggregation parameters with hypertension exists, but causality and clinical utility are, at best, unsettled. And proposed remedies such as “earthing/grounding” remain supported by small, low-quality studies rather than rigorous trials.

This is where conservative caution bites hardest: interesting mechanisms are not clinical practice. If future high-quality work shows that targeting blood rheology meaningfully lowers events, I’ll reconsider. For now, it’s an attractive hypothesis in search of robust evidence.

9) What about the old British trial that “proved” BP drugs don’t save lives?

The author highlights the MRC Mild Hypertension Trial (1970s–80s), which randomised 17,354 adults to bendrofluazide, propranolol, or placebo. It did show a marked reduction in stroke, a reduction in the composite of cardiovascular events, but no difference in all-cause mortality. That’s true as far as it goes—and totally consistent with the drug landscape of the time. (PubMed)

A lot has changed since then: different classes, different combinations, far better risk management for lipids and thrombosis, and better blood-pressure targets for high-risk groups. When current data are pooled—see the Lancet IPD collaborations—the overall benefits of lowering BP are broader than that one era-defining trial could show. (The Lancet)

History is helpful; it isn’t the last word.

10) Harms are real—so build them into the decision, don’t wave them away

Older people fall. Polypharmacy magnifies that. Observational work in community-dwelling elders links antihypertensive use—especially at moderate/high intensity—to more serious fall injuries. In SPRINT, intensive control cut events and mortality but increased hypotension, syncope, electrolyte derangements and AKI; that’s a real tax, not a rounding error. (Cochrane Library, PubMed)

Conservatism, here, is not anti-medicine. It’s pro-trade-offs. If a frail 84-year-old with orthostatic dizziness and a recent wrist fracture is running at 134/72 on three agents, I’d rather accept the “imperfect” number, simplify the regimen, and protect her from harm. If a 58-year-old man with CKD and LVH is at 148/88, I’ll push harder—because his absolute benefit is likely high, and the class choices (e.g., an ACE inhibitor) can help his kidneys and heart beyond the number on the screen.

11) So—scam or not?

The polemic fails because it over-generalises. It wraps genuine critique (bad measurement, indiscriminate targets, neglect of side-effects) into a sweeping assertion that treatment doesn’t really prevent heart disease. The trials say otherwise. At the same time, medical culture has at times behaved like a factory—set a new numerical target, push pills until the number is met, and ignore context. That’s not conspiracy; it’s system inertia plus incentives and the seduction of tidy algorithms.

A better settlement is available:

First, measure properly. Sit, rest, correct cuff, multiple readings, both arms. Confirm with home or ambulatory monitoring before diagnosis or escalation. (PMC)

Second, individualise risk and benefit. Use absolute risk to decide how far to go; don’t chase intensive targets in low-risk or frail patients who will mostly pay the harm bill.

Third, choose classes for comorbidity, not only for millimetres. Accept that diuretics, ACE inhibitors, calcium-channel blockers and β-blockers are not interchangeable cogs.

Fourth, fix levers that don’t come in blister packs. Weight, sleep, alcohol, fitness, and salt quality and quantity—each moves the dial modestly on its own, and together they matter more than our nihilists admit. (NICE, ATS Journals)

Fifth, de-prescribe when life changes. Blood vessels stiffen with age; the brain and kidneys tolerate hypotension poorly. What was appropriate at 60 may be overkill at 80.

If that sounds cautious, good. Prudence isn’t fashionable, but it keeps people out of hospital.

Bibliography

• Blood pressure lowering: individual participant meta-analyses
  Rahimi K, et al. Lancet 2021;398:1053–64. “Pharmacological blood-pressure lowering for primary and secondary prevention …” (The Lancet)
  Ettehad D, et al. Lancet 2016;387:957–67. “Blood pressure lowering for prevention of cardiovascular disease …” (The Lancet)
• SPRINT trial and intensive targets
  SPRINT Research Group. NEJM 2015;373:2103–16. “A Randomized Trial of Intensive versus Standard Blood-Pressure Control.” (New England Journal of Medicine)
  SPRINT Final Report. NEJM 2021;384:1921–30. “Final Report of a Trial of Intensive versus Standard Blood-Pressure Control.” (New England Journal of Medicine, PubMed)
• Emergency department management of high BP
  Alley WD, Copelin EL. “Hypertensive Urgency.” StatPearls (updated 2023). (NCBI)
• White-coat hypertension review
  Cohen JB, et al. “White Coat Hypertension & Cardiovascular Outcomes.” Curr Hypertens Rep 2024 (PMC review). (PMC)
• Historical UK trial of mild hypertension
  Medical Research Council Working Party. BMJ 1985;291:97–104. “MRC trial of treatment of mild hypertension: principal results.” (PubMed)
• Salt and blood pressure evidence
  NICE (expert testimony paper). “Salt and cardiovascular disease: evidence from RCTs & population studies.” (PH25 evidence pack). (NICE)
• Falls and antihypertensives
  Tinetti ME, et al. “Antihypertensive Medications and Serious Fall Injuries.” JAMA Intern Med 2014. (Cochrane Library)
• Sleep and vascular function
  Shah R, et al. “Sleep Deprivation Impairs Vascular Function in Healthy Women.” Ann Am Thorac Soc 2022. (ATS Journals)
• Renal artery stenosis & secondary hypertension
  Arab SF, et al. “Review of Renal Artery Stenosis and Hypertension.” Saudi J Kidney Dis Transpl 2022. (Lippincott Journals)
• Threshold debate
  Port S, et al. “Systolic blood pressure and mortality.” Lancet 2000;355:175–80. (PubMed)

(Where I’ve cited reviews, those pieces themselves reference the primary RCTs and cohort studies that add further depth.)